{"keywords":[],"id":"42219","type":"Disease","alternate_symbols":[],"xrefs":[],"name":"Arthrogryphosis","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42217","type":"Disease","alternate_symbols":[],"xrefs":[],"name":"Abnormality of corpus callosum","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42218","type":"Disease","alternate_symbols":[],"xrefs":[],"name":"Prenatal anemia","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"41367","type":"Disease","alternate_symbols":[],"xrefs":[],"name":"Distal hereditary motor neuropathy associated with upper motor neuron signs","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42223","type":"Disease","alternate_symbols":[],"xrefs":[],"name":"Progressive cone dystrophy (without rod involvement)","medgen_id":"C0271092","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42220","type":"Disease","alternate_symbols":[],"xrefs":[],"name":"Muscle dystrophy","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42224","type":"Disease","alternate_symbols":[],"xrefs":[],"name":"Retinal vascular dystrophy","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"40776","type":"Disease","alternate_symbols":[],"xrefs":[],"name":"Birt-Hogg-Dub√© Syndrome","medgen_id":"CN257768","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"9515","type":"Disease","alternate_symbols":[],"xrefs":[],"name":"Kidney Disease","attribute_content":[],"alternate_names":["Kidney Diseases"]}
{"keywords":[],"id":"40413","type":"Disease","alternate_symbols":[],"xrefs":[],"name":"Epidermolysis bullosa dystrophica, autosomal recessive, modifier of","medgen_id":"C2675760","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42221","type":"Disease","alternate_symbols":[],"xrefs":[],"name":"Internal malformations","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"5531","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301694\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1521\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","alternate_symbols":["ANOP1"],"xrefs":["{\"db\":\"Gene\",\"id\":\"289\"}","{\"db\":\"OMIM\",\"id\":\"301590\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"85275\"}","{\"db\":\"OMIM\",\"id\":\"301590\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ANOP1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Microphthalmia+syndromic+4/4788\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5066\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1521\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"301590\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5066\",\"ref_field\":\"symbol\"}"],"name":"Microphthalmia syndromic 4","medgen_id":"C1844948","public_definition":"Lenz microphthalmia syndrome (LMS) is characterized by unilateral or bilateral microphthalmia and/or clinical anophthalmia with malformations of the ears, teeth, fingers, skeleton, and/or genitourinary system. Microphthalmia is often accompanied by microcornea and glaucoma. Coloboma is present in approximately 60% of microphthalmic eyes with severity ranging from isolated iris coloboma to coloboma of the ciliary body, choroid, and optic disk. Ears may be low set, anteverted, posteriorly rotated, simple, cup shaped, or abnormally modeled. Hearing loss has been observed. Dental findings include irregularly shaped, missing, or widely spaced teeth. Duplicated thumbs, syndactyly, clinodactyly, camptodactyly, and microcephaly are common, as are narrow/sloping shoulders, underdeveloped clavicles, kyphoscoliosis, exaggerated lumbar lordosis, long cylindric thorax, and webbed neck. Genitourinary anomalies include hypospadias, cryptorchidism, renal hypoplasia/aplasia, and hydroureter. Approximately 60% of affected males have mild-to-severe intellectual disability or developmental delay.","attribute_content":[],"alternate_names":[],"symbol":"MCOPS4"}
{"keywords":[],"id":"14978","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"MeSH\",\"id\":\"D009455\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7191\",\"ref_field\":\"name\"}"],"name":"Neurofibroma","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42207","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"93111\"}","{\"db\":\"NCBI for submitter\",\"id\":\"vr002\",\"ref_field\":\"name\"}"],"name":"Renal cysts and diabetes syndrome","medgen_id":"CN206512","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42252","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"98505\"}"],"name":"Genetic motor neuron disease","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42226","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"98733\"}","{\"db\":\"Orphanet\",\"id\":\"98733\",\"ref_field\":\"name\"}"],"name":"Noonan syndrome and Noonan-related syndrome","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42251","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"140465\"}"],"name":"Autosomal dominant distal hereditary motor neuropathy","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"9573","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301515\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1341\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110944\",\"@Source\":\"pmc\"}}]}","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"231178\"}","{\"db\":\"SNOMED CT\",\"id\":\"232058008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1341\",\"ref_field\":\"public_definition\"}"],"name":"Usher syndrome type 2","medgen_id":"C0339534","public_definition":"Usher syndrome type II is characterized by: Congenital, bilateral sensorineural hearing loss that is mild to moderate in the low frequencies and severe to profound in the higher frequencies; Intact vestibular responses; and Retinitis pigmentosa (RP). RP is progressive, bilateral, symmetric retinal degeneration that begins with night blindness and constricted visual fields (tunnel vision) and eventually includes decreased central visual acuity; the rate and degree of vision loss vary within and among families.","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"16653","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301657\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1484\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"275543\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1484\",\"ref_field\":\"public_definition\"}"],"name":"L1 syndrome","medgen_id":"CN118845","public_definition":"The phenotypic spectrum of L1 syndrome includes: X-linked hydrocephalus with stenosis of the aqueduct of Sylvius (HSAS); MASA syndrome (mental retardation [intellectual disability], aphasia [delayed speech], spastic paraplegia [shuffling gait], adducted thumbs); SPG1 (X-linked complicated hereditary spastic paraplegia type 1); and X-linked complicated corpus callosum agenesis. Males with HSAS are born with severe hydrocephalus, adducted thumbs, and spasticity; intellectual disability is severe. In less severely affected males, hydrocephalus may be subclinically present and documented only because of developmental delay; intellectual disability ranges from mild (IQ: 50-70) to moderate (IQ: 30-50).","attribute_content":[],"alternate_names":[]}
{"keywords":["Neoplasm"],"id":"5783","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"175510\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"175510\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Polyps, multiple and recurrent inflammatory fibroid, gastrointestinal","medgen_id":"C1868000","attribute_content":[],"alternate_names":[],"symbol":"GISTPS"}
{"keywords":[],"id":"4197","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"271510\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93357\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4970\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"389161008\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"271510\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Sponastrime dysplasia","medgen_id":"C1300260","attribute_content":[],"alternate_names":[],"symbol":"SEMDSP"}
{"keywords":[],"id":"42208","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"301028\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"301027.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"301027.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"301028\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"301028\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"NEPHROTIC SYNDROME, TYPE 20","attribute_content":[],"alternate_names":[],"symbol":"NPHS20"}
{"keywords":[],"id":"42271","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"301029\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"300688.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300688.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300688.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300688.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"301029\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"301029\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"SHUKLA-VERNON SYNDROME","attribute_content":[],"alternate_names":[],"symbol":"SHUVER"}
{"keywords":[],"id":"42204","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618447\",\"type\":\"MIM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9294\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618447\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Long QT syndrome 8","attribute_content":[],"alternate_names":[],"symbol":"LQT8"}
{"keywords":[],"id":"42209","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618484\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"608441.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608441.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608441.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618484\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618484\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"ARTHROGRYPOSIS MULTIPLEX CONGENITA, MYOGENIC TYPE","attribute_content":[],"alternate_names":[],"symbol":"AMCM"}
{"keywords":[],"id":"42185","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618492\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"603331.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603331.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603331.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618492\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618492\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY AND STRUCTURAL BRAIN ANOMALIES","attribute_content":[],"alternate_names":[],"symbol":"NEDMIBA"}
{"keywords":[],"id":"42211","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618493\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"614584.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614584.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614584.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614584.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614584.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618493\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618493\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"HYPOTONIA, HYPERVENTILATION, IMPAIRED INTELLECTUAL DEVELOPMENT, DYSAUTONOMIA, EPILEPSY, AND EYE ABNORMALITIES","attribute_content":[],"alternate_names":[],"symbol":"HIDEA"}
{"keywords":[],"id":"42212","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618494\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"607462.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607462.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607462.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607462.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607462.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618494\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618494\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"CONGENITAL HYPOTONIA, EPILEPSY, DEVELOPMENTAL DELAY, AND DIGITAL ANOMALIES","attribute_content":[],"alternate_names":[],"symbol":"CHEDDA"}
{"keywords":[],"id":"42213","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618495\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618495\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CD122 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"618495\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IL2RB DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"618495\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INTERLEUKIN 2 RECEPTOR, BETA, DEFICIENCY OF\"}","{\"db\":\"OMIM\",\"id\":\"146710.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"146710.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"146710.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"146710.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618495\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618495\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"IMMUNODEFICIENCY 63 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY","attribute_content":[],"alternate_names":["CD122 DEFICIENCY","IL2RB DEFICIENCY","INTERLEUKIN 2 RECEPTOR, BETA, DEFICIENCY OF"],"symbol":"IMD63"}
{"keywords":[],"id":"42205","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618496\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"607528.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607528.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618496\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618496\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"AORTIC VALVE DISEASE 3","attribute_content":[],"alternate_names":[],"symbol":"AOVD3"}
{"keywords":[],"id":"42214","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618497\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"601012.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601012.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601012.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601012.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618497\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618497\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"NEURODEVELOPMENTAL DISORDER WITH SEIZURES AND NONEPILEPTIC HYPERKINETIC MOVEMENTS","attribute_content":[],"alternate_names":[],"symbol":"NEDNEH"}
{"keywords":[],"id":"42206","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618498\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"617266.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617266.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618498\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618498\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"POLYDACTYLY, POSTAXIAL, TYPE A10","attribute_content":[],"alternate_names":[],"symbol":"PAPA10"}
{"keywords":[],"id":"42210","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618499\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"608435.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608435.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608435.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618499\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618499\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"NOONAN SYNDROME 11","attribute_content":[],"alternate_names":[],"symbol":"NS11"}
{"keywords":[],"id":"42222","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618500\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"604917.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618500\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"HOLOPROSENCEPHALY 12 WITH OR WITHOUT PANCREATIC AGENESIS","attribute_content":[],"alternate_names":[],"symbol":"HPE12"}
{"keywords":[],"id":"42249","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618501\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"607082.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607082.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607082.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607082.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618501\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618501\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"CEREBELLAR ATROPHY WITH SEIZURES AND VARIABLE DEVELOPMENTAL DELAY","attribute_content":[],"alternate_names":[],"symbol":"CASVDD"}
{"keywords":[],"id":"42240","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618504\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618504\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, AUTOSOMAL RECESSIVE 71\"}","{\"db\":\"OMIM\",\"id\":\"613306.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613306.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618504\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618504\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL RECESSIVE 71","attribute_content":[],"alternate_names":["MENTAL RETARDATION, AUTOSOMAL RECESSIVE 71"],"symbol":"MRT71"}
{"keywords":[],"id":"42239","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618505\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"611577.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"611577.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"611577.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"611577.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"611577.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618505\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618505\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"NEURODEVELOPMENTAL DISORDER WITH COARSE FACIES AND MILD DISTAL SKELETAL ABNORMALITIES","attribute_content":[],"alternate_names":[],"symbol":"NEDCFSA"}
{"keywords":[],"id":"42216","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618506\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"184430.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"184430.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"184430.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"184430.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618506\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618506\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"COFFIN-SIRIS SYNDROME 10","attribute_content":[],"alternate_names":[],"symbol":"CSS10"}
{"keywords":[],"id":"42241","type":"Disease","alternate_symbols":["CMT6C"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618511\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618511\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, TYPE 6C\"}","{\"db\":\"OMIM\",\"id\":\"618511\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HMSN VIC\"}","{\"db\":\"OMIM\",\"id\":\"618511\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT6C\"}","{\"db\":\"OMIM\",\"id\":\"179020.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"179020.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618511\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618511\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIC, WITH OPTIC ATROPHY","attribute_content":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, TYPE 6C","HMSN VIC"],"symbol":"HMSN6C"}
{"keywords":[],"id":"42272","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618512\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618512\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618512\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"O''''DONNELL-LURIA-RODAN SYNDROME","attribute_content":[],"alternate_names":[],"symbol":"ODLURO"}
{"keywords":[],"id":"42257","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618513\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618513\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618513\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"LEBER CONGENITAL AMAUROSIS 19","attribute_content":[],"alternate_names":[],"symbol":"LCA19"}
{"keywords":[],"id":"9552","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301457\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1280\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"PS167200\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"2309\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10753\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"39427000\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1280\",\"ref_field\":\"public_definition\"}"],"name":"Pachyonychia congenita syndrome","medgen_id":"C0265334","public_definition":"Pachyonychia congenita (PC) is characterized by hypertrophic nail dystrophy, painful palmoplantar keratoderma and blistering, oral leukokeratosis, pilosebaceous cysts (including steatocystoma and vellus hair cysts), palmoplantar hyperhydrosis, and follicular keratoses on the trunk and extremities.","attribute_content":[],"alternate_names":[],"symbol":"PC"}
{"keywords":[],"id":"22353","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001395\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001395\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6598\",\"ref_field\":\"name\"}","{\"db\":\"Undiagnosed Diseases Network,NIH\",\"id\":\"d416e474-c254-4384-9e32-a91cfe7608f0_1\",\"ref_field\":\"name\"}","{\"db\":\"Undiagnosed Diseases Network,NIH\",\"id\":\"d416e474-c254-4384-9e32-a91cfe7608f0_2\",\"ref_field\":\"name\"}"],"name":"Hepatic fibrosis","medgen_id":"C0239946","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42181","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Ege University Pediatric Genetics,Ege University\",\"id\":\"INHP_16\",\"ref_field\":\"name\"}"],"name":"CPT deficiency, hepatic, type IA","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42180","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Ege University Pediatric Genetics,Ege University\",\"id\":\"INHP_50\",\"ref_field\":\"name\"}"],"name":"Peroxisome biogenesis disorder","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42183","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Ege University Pediatric Genetics,Ege University\",\"id\":\"INHP_154\",\"ref_field\":\"name\"}"],"name":"Xeroderma pigmentosum, group E, DDB-negative subtype","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42182","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Ege University Pediatric Genetics,Ege University\",\"id\":\"INHP_160\",\"ref_field\":\"name\"}"],"name":"Crisponi/Cold-induced sweating syndrome","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42184","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Ege University Pediatric Genetics,Ege University\",\"id\":\"INHP_45_1\",\"ref_field\":\"name\"}"],"name":"Glutaricaciduria, type I","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42179","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"Ege University Pediatric Genetics,Ege University\",\"id\":\"INHP_178_1\",\"ref_field\":\"name\"}"],"name":"Ataxia telangiectasi","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42243","type":"Disease","alternate_symbols":[],"xrefs":["{\"db\":\"International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine\",\"id\":\"FG2019-15\",\"ref_field\":\"name\"}"],"name":"22q11.2 central duplication syndrome","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"41122","type":"Finding","alternate_symbols":[],"xrefs":[],"name":"Holoprosencephaly","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42254","type":"Finding","alternate_symbols":[],"xrefs":[],"name":"Ataxia with Dysarthria","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"41348","type":"Finding","alternate_symbols":[],"xrefs":[],"name":"myoglobinopathy","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"21723","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000537\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000537\",\"ref_field\":\"name\"}"],"name":"Epicanthus inversus","medgen_id":"C1303003","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"22354","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001396\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001396\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1283\",\"ref_field\":\"name\"}","{\"db\":\"The Raphael Recanati Genetics Institute,Rabin Medical Center\",\"id\":\"SUB4493571\",\"ref_field\":\"name\"}"],"name":"Cholestasis","medgen_id":"C0008370","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"22427","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001507\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008904\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001507\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abnormal growth\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001507\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Growth issue\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001507\",\"ref_field\":\"name\"}"],"name":"Growth abnormality","medgen_id":"C0262361","attribute_content":[],"alternate_names":["Abnormal growth","Growth issue"]}
{"keywords":[],"id":"23084","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002451\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002451\",\"ref_field\":\"name\"}"],"name":"Limb dystonia","medgen_id":"C0751093","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"29750","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011858\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011858\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Low factor IX activity\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011858\",\"ref_field\":\"name\"}"],"name":"Reduced factor IX activity","medgen_id":"C4023159","attribute_content":[],"alternate_names":["Low factor IX activity"]}
{"keywords":[],"id":"37354","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0025356\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0025356\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pschomotor retardation\"}"],"name":"Psychomotor retardation","medgen_id":"C0424230","attribute_content":[],"alternate_names":["Pschomotor retardation"]}
{"keywords":[],"id":"32384","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0030153\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0030153\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Bile duct cancer\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0030153\",\"ref_field\":\"name\"}"],"name":"Cholangiocarcinoma","medgen_id":"C0206698","attribute_content":[],"alternate_names":["Bile duct cancer"]}
{"keywords":[],"id":"42236","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"Undiagnosed Diseases Network,NIH\",\"id\":\"7df30372-0735-4620-ac50-e816ba1b4f29_1\",\"ref_field\":\"name\"}"],"name":"GP130-deficient hyper-IgE syndrome","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42234","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"Undiagnosed Diseases Network,NIH\",\"id\":\"a6b70e9a-d4a4-4d79-a00d-d545e8926ce5_1\",\"ref_field\":\"name\"}"],"name":"LONP1-related condition","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42237","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"Undiagnosed Diseases Network,NIH\",\"id\":\"b619eb6f-6dc9-4dd8-8fc9-5447807d920c_1\",\"ref_field\":\"name\"}"],"name":"SPTBN1-related neurodevelopmental disease","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42233","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"Undiagnosed Diseases Network,NIH\",\"id\":\"b7b0e2be-80f1-4885-9ea8-b8642f530f64_1\",\"ref_field\":\"name\"}"],"name":"NBEA-related developmental delay and generalized epilepsy","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42235","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"Undiagnosed Diseases Network,NIH\",\"id\":\"e2559e3e-95e7-4697-bb21-8c082bbc8def_2\",\"ref_field\":\"name\"}"],"name":"PIGQ-related condition","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42242","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine\",\"id\":\"FG2019-10\",\"ref_field\":\"name\"}"],"name":"22q11.2 central deletion syndrome","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"42244","type":"Finding","alternate_symbols":[],"xrefs":["{\"db\":\"International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine\",\"id\":\"FG2019-17\",\"ref_field\":\"name\"}"],"name":"22q11.2 distal duplication syndrome","attribute_content":[],"alternate_names":[]}
{"keywords":[],"id":"41320","content":"{\"Citation\":[{\"@Abbrev\":\"Medical Genetics Summaries\",\"@Type\":\"review\",\"ID\":{\"$\":\"NBK537365\",\"@Source\":\"BookShelf\"}},{\"@Abbrev\":\"DailyMed Drug Label, 2017\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"DailyMed Drug Label, FLURBIPROFEN, 2017\"},\"URL\":{\"$\":\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e5c06f1-f279-4f2f-b10d-0f70005a27e6\"}}]}","type":"DrugResponse","alternate_symbols":[],"xrefs":["{\"db\":\"Medical Genetics Summaries\",\"id\":\"NBK537365\",\"ref_field\":\"public_definition\"}"],"name":"Flurbiprofen response","medgen_id":"CN258139","public_definition":"Flurbiprofen (brand name Ansaid) is a nonsteroidal anti-inflammatory drug (NSAID). Tablets and skin patches are used in the management of osteoarthritis and rheumatoid arthritis. Flurbiprofen provides pain relief and reduces inflammation. Flurbiprofen eye drops (brand name Ocufen) may also be used to prevent miosis (excessive constriction of the pupil) during eye operations; e.g., cataract surgery. Flurbiprofen is primarily metabolized by CYP2C9. Individuals who lack CYP2C9 activity (CYP2C9 poor metabolizers) have an increased exposure to flurbiprofen, and an increased risk of side effects. Like all NSAIDs, flurbiprofen increases the risk of serious cardiovascular events, including myocardial infarction and stroke, and serious gastrointestinal (GI) adverse events such as bleeding, ulceration, and perforation, which may be fatal. The recommended starting dose of flurbiprofen tablets in adults is 200‚Äì300 mg per day, divided for administration 2, 3, or 4 times a day. But for all patients, the lowest effective dose of flurbiprofen should be used for the shortest length of time, consistent with the treatment goals of each individual. The FDA-approved drug label for flurbiprofen states that the dose of flurbiprofen should be reduced in \"patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin and phenytoin)\". This dose reduction is to avoid the abnormally high plasma levels of flurbiprofen in these patients caused by reduced metabolic clearance. However, specific dose reductions based on CYP2C9 phenotype are not provided. As for all NSAIDs, flurbiprofen is contraindicated in patients with a known hypersensitivity; a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or another NSAID; and for coronary artery bypass graft (CABG) surgery. Flurbiprofen should also be avoided by pregnant women starting at 30 weeks gestation.","attribute_content":[],"alternate_names":["Ansaid response","Ocufen response"]}
{"keywords":[],"id":"40174","content":"{\"Citation\":[{\"@Abbrev\":\"Medical Genetics Summaries\",\"@Type\":\"review\",\"ID\":{\"$\":\"NBK537366\",\"@Source\":\"BookShelf\"}},{\"@Abbrev\":\"DailyMed Drug Label, 2018\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"DailyMed Drug Label, ZURAMPIC, 2018\"},\"URL\":{\"$\":\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef9e7711-f478-4e35-bf4e-6021c8457e3b\"}}]}","type":"DrugResponse","alternate_symbols":[],"xrefs":["{\"db\":\"Medical Genetics Summaries\",\"id\":\"NBK537366\",\"ref_field\":\"public_definition\"}"],"name":"Lesinurad response","medgen_id":"CN248784","public_definition":"Lesinurad (brand name Zurampic) is a urate transport inhibitor used in the treatment of gout. Gout is one of the most common types of inflammatory arthritis, affecting approximately 3% of adults worldwide. It is caused by the accumulation of urate crystals in joints. The long-term management of gout includes reducing risk factors (e.g., obesity, alcohol use, diuretic use, poor renal function), and medication to lower uric acid levels. Lesinurad reduces the high level of uric acid (hyperuricemia) associated with gout. Lesinurad should only be used in combination with a xanthine oxidase inhibitor (e.g., allopurinol, febuxostat) ‚Äì‚Äì the risk of acute renal failure is increased if lesinurad is used alone. The addition of lesinurad to gout treatment is reserved for patients who have failed to achieve their target uric acid level despite being treated with a xanthine oxidase inhibitor. Xanthine oxidase inhibitors reduce uric acid by inhibiting its production, whereas lesinurad reduces uric acid by blocking its reabsorption in the kidney. Lesinurad is primarily metabolized by CYP2C9 to several inactive metabolites. Individuals who lack CYP2C9 activity (\"CYP2C9 poor metabolizers\") have an increased exposure to lesinurad, and an increased risk of side effects. Adverse reactions of lesinurad therapy include kidney stones and other kidney problems. Lesinurad is also associated with an increased risk of cardiovascular events. The FDA-approved drug label for lesinurad states that lesinurad should be used with caution in CYP2C9 poor metabolizers, but does not provide specific dose adjustments in this group. The standard dose of lesinurad is 200 mg daily. Lesinurad is contraindicated in patients with severe impairment of kidney function (e.g., kidney transplant and hemodialysis patients) as well as individuals with tumor lysis syndrome or Lesch-Nyhan syndrome.","attribute_content":[],"alternate_names":["Zurampic response"]}
{"keywords":[],"id":"41352","content":"{\"Citation\":[{\"@Abbrev\":\"Medical Genetics Summaries\",\"@Type\":\"review\",\"ID\":{\"$\":\"NBK537367\",\"@Source\":\"BookShelf\"}},{\"@Abbrev\":\"DailyMed Drug Label, 2018\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"DailyMed Drug Label, PIROXICAM, 2018\"},\"URL\":{\"$\":\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6335245-7e04-46b9-a505-f47647781e19\"}}]}","type":"DrugResponse","alternate_symbols":[],"xrefs":["{\"db\":\"Medical Genetics Summaries\",\"id\":\"NBK537367\",\"ref_field\":\"public_definition\"}"],"name":"Piroxicam response","medgen_id":"CN258188","public_definition":"Piroxicam (brand name Feldene) is a nonsteroidal anti-inflammatory drug (NSAID) used to treat osteoarthritis and rheumatoid arthritis. Piroxicam provides pain relief and reduces inflammation. \r\nPiroxicam is primarily metabolized by CYP2C9. Individuals who lack CYP2C9 activity (\"CYP2C9 poor metabolizers\") have an increased exposure to piroxicam, and an increased risk of side effects.\r\nLike all NSAIDs, piroxicam increases the risk of serious cardiovascular events, including myocardial infarction and stroke, and serious gastrointestinal (GI) adverse events such as bleeding, ulceration, and perforation.\r\nThe standard dose of piroxicam for osteoarthritis and rheumatoid arthritis in adults is 20 mg once daily. But for all patients, the lowest effective dose of piroxicam should be used for the shortest length of time, consistent with the treatment goals of each individual.\r\nThe FDA-approved drug label for piroxicam states that a dose reduction should be considered in \"patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin and phenytoin)\". Dose reductions should be considered because these patients may have abnormally high plasma levels of piroxicam caused by reduced metabolic clearance. However, specific dose reductions based on CYP2C9 phenotype are not provided.\r\nAs for all NSAIDs, piroxicam is contraindicated in patients with a known hypersensitivity, a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or another NSAID, and following coronary artery bypass graft (CABG) surgery. Piroxicam should also be avoided by pregnant women starting at 30 weeks gestation.","attribute_content":[],"alternate_names":["Feldene response"]}
